343 related articles for article (PubMed ID: 21784355)
21. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings.
Wimo A; Reed CC; Dodel R; Belger M; Jones RW; Happich M; Argimon JM; Bruno G; Novick D; Vellas B; Haro JM
J Alzheimers Dis; 2013; 36(2):385-99. PubMed ID: 23629588
[TBL] [Abstract][Full Text] [Related]
22. Identifying factors of activities of daily living important for cost and caregiver outcomes in Alzheimer's disease.
Reed C; Belger M; Vellas B; Andrews JS; Argimon JM; Bruno G; Dodel R; Jones RW; Wimo A; Haro JM
Int Psychogeriatr; 2016 Feb; 28(2):247-59. PubMed ID: 26307191
[TBL] [Abstract][Full Text] [Related]
23. Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials.
Bernick C; Cummings J; Raman R; Sun X; Aisen P
Arch Neurol; 2012 Jul; 69(7):901-5. PubMed ID: 22431834
[TBL] [Abstract][Full Text] [Related]
24. Factors associated with long-term impact on informal caregivers during Alzheimer's disease dementia progression: 36-month results from GERAS.
Reed C; Belger M; Scott Andrews J; Tockhorn-Heidenreich A; Jones RW; Wimo A; Dodel R; Haro JM
Int Psychogeriatr; 2020 Feb; 32(2):267-277. PubMed ID: 31134870
[TBL] [Abstract][Full Text] [Related]
25. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective.
Jones RW; McCrone P; Guilhaume C
Drugs Aging; 2004; 21(9):607-20. PubMed ID: 15260515
[TBL] [Abstract][Full Text] [Related]
26. Application of Resource Utilization in Dementia (RUD) instrument in a global setting.
Wimo A; Gustavsson A; Jönsson L; Winblad B; Hsu MA; Gannon B
Alzheimers Dement; 2013 Jul; 9(4):429-435.e17. PubMed ID: 23142433
[TBL] [Abstract][Full Text] [Related]
27. Determinants of societal costs in Alzheimer's disease: GERAS study baseline results.
Dodel R; Belger M; Reed C; Wimo A; Jones RW; Happich M; Argimon JM; Bruno G; Vellas B; Haro JM
Alzheimers Dement; 2015 Aug; 11(8):933-45. PubMed ID: 25846298
[TBL] [Abstract][Full Text] [Related]
28. Differences in resource use and costs of dementia care between European countries: baseline data from the ICTUS study.
Gustavsson A; Jonsson L; Rapp T; Reynish E; Ousset PJ; Andrieu S; Cantet C; Winblad B; Vellas B; Wimo A;
J Nutr Health Aging; 2010 Oct; 14(8):648-54. PubMed ID: 20922341
[TBL] [Abstract][Full Text] [Related]
29. Cognitive impairment after stroke - impact on activities of daily living and costs of care for elderly people. The Göteborg 70+ Stroke Study.
Claesson L; Lindén T; Skoog I; Blomstrand C
Cerebrovasc Dis; 2005; 19(2):102-9. PubMed ID: 15608434
[TBL] [Abstract][Full Text] [Related]
30. Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational Study.
Rapp T; Andrieu S; Chartier F; Deberdt W; Reed C; Belger M; Vellas B
Value Health; 2018 Mar; 21(3):295-303. PubMed ID: 29566836
[TBL] [Abstract][Full Text] [Related]
31. A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial.
Molloy DW; Standish TI; Zhou Q; Guyatt G;
Int J Geriatr Psychiatry; 2013 May; 28(5):463-70. PubMed ID: 22718435
[TBL] [Abstract][Full Text] [Related]
32. Methodological challenges in assessing the impact of comorbidities on costs in Alzheimer's disease clinical trials.
Kahle-Wrobleski K; Fillit H; Kurlander J; Reed C; Belger M
Eur J Health Econ; 2015 Dec; 16(9):995-1004. PubMed ID: 25410743
[TBL] [Abstract][Full Text] [Related]
33. Exploring the relationship between Alzheimer's disease severity and longitudinal costs.
Rapp T; Andrieu S; Molinier L; Grand A; Cantet C; Mullins CD; Vellas B
Value Health; 2012 May; 15(3):412-9. PubMed ID: 22583450
[TBL] [Abstract][Full Text] [Related]
34. Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer's disease.
Bergvall N; Brinck P; Eek D; Gustavsson A; Wimo A; Winblad B; Jönsson L
Int Psychogeriatr; 2011 Feb; 23(1):73-85. PubMed ID: 20619068
[TBL] [Abstract][Full Text] [Related]
35. Prevalence, resource utilization and costs of vascular dementia compared to Alzheimer's dementia in a population setting.
Sicras A; Rejas J; Arco S; Flores E; Ortega G; Esparcia A; Suárez A; Gordillo MJ
Dement Geriatr Cogn Disord; 2005; 19(5-6):305-15. PubMed ID: 15785031
[TBL] [Abstract][Full Text] [Related]
36. Predictors of costs of care in Alzheimer's disease: a multinational sample of 1222 patients.
Gustavsson A; Brinck P; Bergvall N; Kolasa K; Wimo A; Winblad B; Jönsson L
Alzheimers Dement; 2011 May; 7(3):318-27. PubMed ID: 21575872
[TBL] [Abstract][Full Text] [Related]
37. Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer's disease: 18-month UK results from the GERAS observational study.
Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW
BMC Geriatr; 2016 Nov; 16(1):195. PubMed ID: 27887645
[TBL] [Abstract][Full Text] [Related]
38. Costs and Resource Use Associated with Alzheimer's Disease in Italy: Results from an Observational Study.
Bruno G; Mancini M; Bruti G; Dell'Agnello G; Reed C
J Prev Alzheimers Dis; 2018; 5(1):55-64. PubMed ID: 29405234
[TBL] [Abstract][Full Text] [Related]
39. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease.
Wimo A; Winblad B; Stöffler A; Wirth Y; Möbius HJ
Pharmacoeconomics; 2003; 21(5):327-40. PubMed ID: 12627986
[TBL] [Abstract][Full Text] [Related]
40. Relationship between global severity of patients with Alzheimer's disease and costs of care in Spain; results from the co-dependence study in Spain.
Darbà J; Kaskens L; Lacey L
Eur J Health Econ; 2015 Nov; 16(8):895-905. PubMed ID: 25348897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
